Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 3 of 18 for:    Ustekinumab | Open Studies

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2015 by Janssen Research & Development, LLC
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT02349061
First received: January 23, 2015
Last updated: NA
Last verified: January 2015
History: No changes posted
  Purpose

The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in which there can be skin rash, arthritis, kidney problems, and anemia, among other problems).


Condition Intervention Phase
Systemic Lupus Erythematosus
Drug: Ustekinumab
Drug: Placebo
Other: Concomitant Medication
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Percentage of Participants With a Composite SRI-4 Response at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    Systemic Lupus Erythematosus Responder index (SRI-4) is defined as greater than or equal to (>=) 4 point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, no new domain scores in either British Isles Lupus Assessment Group (BILAG) A or B and no worsening (less than [˂] 10 millimeters [mm] increase) from baseline in the Physician's Global Assessment of Disease Activity (PGA). The SLEDAI - 2k assessment consists of 24 items which has total score of 0 to 105, with higher scores representing increased disease activity. The BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 8 organ systems. For each organ system, letter score was given: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale (VAS) = from 'very well' (0) to 'very poor' (10).


Secondary Outcome Measures:
  • Change From Baseline in SLEDAI-2K Score at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    Systemic lupus erythematosus disease activity index 2000 (SLEDAI - 2k) assessment consists of 24 items. A weighted score of 8, 4, 2, and 1 were assigned for items 1 to 8, items 9 to 14, items 15 to 21, and items 22 to 24, respectively. A SLEDAI global score for Systemic lupus erythematosus (SLE) disease activity was derived by adding all weighted scores. Total possible score range for SLEDAI - 2K global score is 0 to 105, with higher scores representing increased disease activity.

  • Change From Baseline in Physician Global Assessment of Disease Activity (PGA) at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The Physician Global Assessment of Disease Activity will be recorded on a visual analogue scale (VAS = 0 to 10 centimeters [cm]). The scale for the assessments range from 'no lupus activity' (0) to 'extremely active lupus' (10).

  • Percentage of Participants With BICLA Response at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The BILAG-based Combined Lupus Assessment (BICLA) requires participants to meet response criteria across 3 assessment tools and no treatment failure must be recorded: 1) BILAG improvement classified as: a) All BILAG A scores at baseline improved to either BILAG B, C or D b) All BILAG B scores at baseline improved to either BILAG C or D, c) No worsening in disease activity defined as no new BILAG A scores and <= 1 new BILAG B score. 2) No worsening of total SLEDAI-2K from baseline (change <= 0). 3) No significant deterioration (<10 mm increase) in 100 mm visual analogue PGA scale.


Estimated Enrollment: 100
Study Start Date: April 2015
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40. Participants will maintain stable concomitant treatment through Week 48, with safety follow-up through Week 56.
Drug: Ustekinumab
Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40. Participants will maintain stable concomitant treatment through Week 48, with safety follow-up through Week 56.
Other Name: STELARA
Drug: Placebo
Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16 to Group 2. At week 24 participants will receive ustekinumab subcutaneously at every 8 weeks up to Week 40 to Group 1.
Other: Concomitant Medication
Participants are to maintain stable concomitant treatment (azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, anti-hypertensive medications, and topical medications) through Week 48, with safety follow-up through Week 56.
Experimental: Group 2
Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At Week 24 participants will cross-over and will receive ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40. Participants will maintain stable concomitant treatment through Week 48, with safety follow-up through Week 56.
Drug: Ustekinumab
Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40. Participants will maintain stable concomitant treatment through Week 48, with safety follow-up through Week 56.
Other Name: STELARA
Drug: Placebo
Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16 to Group 2. At week 24 participants will receive ustekinumab subcutaneously at every 8 weeks up to Week 40 to Group 1.
Other: Concomitant Medication
Participants are to maintain stable concomitant treatment (azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, anti-hypertensive medications, and topical medications) through Week 48, with safety follow-up through Week 56.

Detailed Description:

A multicenter (more than one medical research center involved in study), randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know about the study drug), placebo-controlled, proof-of-concept study of ustekinumab in participants with active systemic lupus erythematosus. Participants will be screened to achieve all inclusion criteria and none exclusion criteria and will then receive either ustekinumab or placebo along with concomitant background medicine. Participants will be primarily assessed for response using the Systemic Lupus Erythematosus Response Index 2000 (SRI-4). Participants' safety will be assessed throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have documented medical history to meet SLICC classification criteria for SLE for a minimum of 3 months prior to first dose
  • At least 1 well-documented (subject file, referring physician letter, or laboratory result), unequivocally positive, test for autoantibodies in medical history including either of the following: ANA, and/or anti-dsDNA antibodies, and/or anti-Smith antibodies
  • At least 1 unequivocally positive autoantibody test including ANA and/or anti-dsDNA antibodies and/or anti-Smith antibodies detected during screening
  • At least 1 BILAG A and/or 2 BILAG B domain scores observed at screening and/or at Week 0 prior to first administration of study agent
  • Demonstrate active disease based on SLEDAI-2K score greater than or equal to (>=) 6 observed during screening and assessed approximately 2 to 6 weeks prior to randomization (Week 0). Must also have SLEDAI-2K score >= 4 for clinical features (ie, SLEDAI excluding laboratory-based items) at Week 0 prior to the first administration of study agent

Exclusion Criteria:

  • Have other inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), RA/lupus overlap, psoriasis or Lyme disease
  • Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in the study or within 4 months after receiving the last administration of study agent
  • Have received systemic immunosuppressives other than those described in inclusion criteria within the past 6 months prior to first administration of study agent (Section 4.1).
  • Have received more than 1 previous B cell targeting therapy including belimumab or epratuzamab within 6 months prior to first administration of the study agent or received B-cell depleting therapy (eg, rituximab) within 12 months prior to first administration of the study agent or have evidence of continued B-cell depletion following such therapy
  • Have ever received ustekinumab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02349061

Contacts
Contact: This study is not yet recruiting patients. Please check back for future recruiting sites, or email JNJ.CT@sylogent.com

Locations
United States, Oregon
Withdrawn
Portland, Oregon, United States
United States, Tennessee
Not yet recruiting
Jackson, Tennessee, United States
United States, Utah
Withdrawn
Salt Lake City, Utah, United States
Australia
Withdrawn
Queensland, Australia
Withdrawn
Sydney, Australia
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

No publications provided

Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT02349061     History of Changes
Other Study ID Numbers: CR106661, CNTO1275SLE2001
Study First Received: January 23, 2015
Last Updated: January 23, 2015
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Germany: Paul-Ehrlich-Institut
Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Mexico: Federal Commission for Sanitary Risks Protection
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Bioethics Committee of Medicines and Medical Devices
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Taiwan : Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Canada: Health Products and Food Branch
Italy: Spett. le Ufficio Ricerca e Sperimentazione Clinica AIFA
Poland: Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych

Keywords provided by Janssen Research & Development, LLC:
Systemic Lupus Erythematosus
Ustekinumab

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on February 27, 2015